Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC

PHASE2CompletedINTERVENTIONAL
Enrollment

541

Participants

Timeline

Start Date

October 10, 2014

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Cisplatin

DRUG

5-Fluorouracile

DRUG

Docetaxel

DRUG

Cetuximab

DRUG

granulocyte colony-stimulating factor (G-CSF)

Trial Locations (17)

12203

Charité Campus Benjamin Franklin, Berlin

13385

Hôpital de la Timone, Marseille

34298

ICM Val d'Aurelle, Montpellier, Montpellier

35042

Centre Eugene Marquis, Rennes

44805

Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Saint-Herblain

54511

L'Institut de Cancérologie de Lorraine (ICL) Alexis Vautrin, Vandœuvre-lès-Nancy

56322

Centre Hospitalier de Bretagne Sud (CHBS), Lorient

69008

Centre Léon Bérard, Lyon

75005

Val de Grace, Paris

76038

Centre Henri Becquerel, Rouen

76600

Clinique des Ormeaux, Le Havre

77150

Centre Médical de Forcilles, Férolles-Attilly

84082

Institut Sainte Catherine, Avignon

94805

Gustave Roussy, Villejuif

Unknown

Centre Hospitalier de la Dracénie, Draguignan

06189

Centre Antoine-Lacassagne, Nice

08907

Instituto Catalá de Oncologia (ICO), Barcelona

All Listed Sponsors
collaborator

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

OTHER

collaborator

AIO-Studien-gGmbH

OTHER

lead

Groupe Oncologie Radiotherapie Tete et Cou

OTHER

NCT02268695 - Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC | Biotech Hunter | Biotech Hunter